These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18284648

  • 1. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM, Meyers NL, Hickling RI.
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.
    Scarpellini E, Tack J.
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1663-70. PubMed ID: 18922103
    [Abstract] [Full Text] [Related]

  • 7. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [Abstract] [Full Text] [Related]

  • 8. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC.
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Scand J Gastroenterol; 2008 Feb 15; 43(10):1202-11. PubMed ID: 18618371
    [Abstract] [Full Text] [Related]

  • 14. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
    Meyers NL, Hickling RI.
    Drugs R D; 2008 Feb 15; 9(1):37-63. PubMed ID: 18095752
    [Abstract] [Full Text] [Related]

  • 15. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S, Nakajima A, Fujiyama Y, Kosako M, Nakagawa A, Akiho H, Nakashima Y, Johnston JM, Miwa H.
    Neurogastroenterol Motil; 2018 May 15; 30(5):e13275. PubMed ID: 29278278
    [Abstract] [Full Text] [Related]

  • 16. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec 15; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 17. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW, Stanghellini V, Geraint M, Halphen M.
    Am J Gastroenterol; 2013 Sep 15; 108(9):1508-15. PubMed ID: 23835436
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 15; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 19. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R.
    Aliment Pharmacol Ther; 2008 Apr 15; 27(8):685-96. PubMed ID: 18248656
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.